Cargando…

Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series

Detalles Bibliográficos
Autores principales:	Zangrillo, Alberto, Landoni, Giovanni, Beretta, Luigi, Morselli, Federica, Serpa Neto, Ary, Bellomo, Rinaldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228670/ https://www.ncbi.nlm.nih.gov/pubmed/32414393 http://dx.doi.org/10.1186/s13054-020-02928-0

Ejemplares similares

Feasibility and safety of angiotensin II administration in general ward patients during COVID-19 pandemic: a case series
por: Morselli, Federica, et al.
Publicado: (2023)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Angiotensin II infusion in COVID‐19: An international, multicenter, registry‐based study
por: Serpa Neto, Ary, et al.
Publicado: (2022)

Angiotensin II in vasodilatory shock: lights and shadows
por: Antonucci, Elio, et al.
Publicado: (2017)

Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients
por: Zangrillo, Alberto, et al.
Publicado: (2023)

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
por: Tumlin, James A., et al.
Publicado: (2018)

Gene Expression Scoring of Immune Activity Levels for Precision Use of Hydrocortisone in Vasodilatory Shock
por: Yao, Lijing, et al.
Publicado: (2022)

Angiotensin II: a new therapeutic option for vasodilatory shock
por: Bussard, Rachel L, et al.
Publicado: (2018)

Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?
por: Buchtele, Nina, et al.
Publicado: (2018)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Non-Adrenergic Vasopressors in Patients with or at Risk for Vasodilatory Shock. A Systematic Review and Meta-Analysis of Randomized Trials
por: Belletti, Alessandro, et al.
Publicado: (2015)

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
por: Wieruszewski, Patrick M., et al.
Publicado: (2023)

How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review
por: Semedi, Bambang Pujo, et al.
Publicado: (2023)

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients
por: Bailey, Dwight M., et al.
Publicado: (2019)

Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
por: Serpa Neto, Ary, et al.
Publicado: (2012)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019)

Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series
por: Tezel, Oguzhan, et al.
Publicado: (2023)

Vasopressin in vasodilatory shock: is the heart in danger?
por: Hauser, Balázs, et al.
Publicado: (2008)

Vasopressin and terlipressin in adult vasodilatory shock
por: Polito, Angelo, et al.
Publicado: (2012)

Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
por: Pereira, VGM, et al.
Publicado: (2013)

Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019–Induced Vasodilatory Shock: A Retrospective Matched Cohort Study
por: Leisman, Daniel E., et al.
Publicado: (2020)

Angiotensin II - A Brief Review and Role in Severe SARS-COV-2 Sepsis
por: Carà, Gianmarco A., et al.
Publicado: (2022)

Advances in Vasodilatory Shock: A Concise Review
por: Lahiry, Sandeep, et al.
Publicado: (2019)

Home ventilators for invasive ventilation of patients with COVID-19
por: Monti, Giacomo, et al.
Publicado: (2023)

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy
por: Zangrillo, Alberto, et al.
Publicado: (2023)

Vasopressin in vasodilatory shock: hemodynamic stabilization at the cost of the liver and the kidney?
por: Bracht, Hendrik, et al.
Publicado: (2007)

Risk factors for severe vasodilatory shock after cardiac surgery
por: Almeida, J, et al.
Publicado: (2015)

A double‐blind randomised feasibility trial of angiotensin‐2 in cardiac surgery(*)
por: Coulson, T. G., et al.
Publicado: (2022)

Recent exposure to smoking and COVID-19
por: Landoni, Giovanni, et al.
Publicado: (2023)

Angiotensin converting enzyme defects in shock: implications for future therapy
por: Chawla, Lakhmir S., et al.
Publicado: (2018)

Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
por: Bendjelid, Karim
Publicado: (2020)

Vasopressor-Refractory Shock From Clozapine Overdose Treated With Synthetic Angiotensin II Infusion
por: Wieruszewski, Patrick M., et al.
Publicado: (2020)

Vasopressin in pediatric vasodilatory shock: a multicentred randomized controlled trial
por: Choong, K, et al.
Publicado: (2009)

Refractory vasodilatory shock secondary to metformin overdose supported with VA ECMO()
por: Ives Tallman, Crystal, et al.
Publicado: (2021)

Renal outcomes according to renal replacement therapy modality and treatment protocol in the ATN and RENAL trials
por: Naorungroj, Thummaporn, et al.
Publicado: (2022)

Angiotensin II in experimental hyperdynamic sepsis
por: Wan, Li, et al.
Publicado: (2009)

Reply: COVID-19 Is Not Comparable to H1N1 Influenza
por: Udy, Andrew A., et al.
Publicado: (2022)

Sodium bicarbonate therapy for metabolic acidosis in critically ill patients: a survey of Australian and New Zealand intensive care clinicians
por: Neto, Ary Serpa, et al.
Publicado: (2023)

Vasopressin in vasodilatory shock: ensure organ blood flow, but take care of the heart!
por: Dünser, Martin W, et al.
Publicado: (2006)

Vasopressin for the treatment of vasodilatory shock: an ESICM systematic review and a meta-analysis
por: Polito, A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_a31olhoj42jib77akkheud3pdu